Work for Madrigal Pharmaceuticals, Inc.?

Claim Your Profile

Madrigal Pharmaceuticals, Inc. Logo Image

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. Banner Image

About Madrigal Pharmaceuticals, Inc.

11-50 Employees
Based in Conshohocken, Pennsylvania

Madrigal Pharmaceuticals, Inc. (Nasdaq Global Select: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in- class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol